Monday, June 6, 2022, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)

Breakfast with the Investigators: Bladder Cancer

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Yohann Loriot, MD, PhD
Deputy Chair, Early Drug Development (DITEP)
Chair, GU Oncology Group
Leader, Resistance to Innovative Drugs Program
Molecular Predictors and New Targets in Oncology, INSERM U981
Gustave Roussy
Villejuif, France

Elizabeth R Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Medical Oncology
Deputy Director, Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania


Jonathan E Rosenberg, MD
Chief, Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Enno W Ercklentz Chair
Memorial Sloan Kettering Cancer Center
New York, New York

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

MODULE 1: Current and Future Management of Nonmetastatic Urothelial Bladder Cancer (UBC)

  • Efficacy and safety findings after extended follow-up from the KEYNOTE-057 trial of pembrolizumab for high-risk non-muscle-invasive bladder cancer (NMIBC) unresponsive or refractory to BCG therapy; selection of patients for pembrolizumab therapy
  • Biologic rationale for the investigation of anti-PD-1/PD-L1 antibodies in combination with BCG for NMIBC; ongoing Phase III trials (eg, ALBAN, KEYNOTE-676, CheckMate 7G8) evaluating this approach
  • Rates of pathologic complete response and other clinically relevant outcomes in early trials evaluating neoadjuvant anti-PD-1/PD-L1 antibody therapy for resectable muscle-invasive bladder cancer (MIBC)
  • Key efficacy and safety results from the Phase III CheckMate 274 trial comparing nivolumab to placebo after radical surgery in patients with high-risk MIBC; recent FDA approval and optimal integration into current treatment
  • Early data with and ongoing trials of neoadjuvant and adjuvant anti-PD-1/PD-L1 antibodies combined with radiation therapy and/or other systemic therapies for MIBC

MODULE 2: First-Line Treatment for Patients with Metastatic UBC (mUBC)

  • Current clinical roles of atezolizumab and pembrolizumab as first-line treatment for mUBC; importance of chemotherapy eligibility and PD-L1 status in patient selection
  • Key efficacy and safety data with maintenance avelumab after front-line chemotherapy in patients with mUBC; appropriate incorporation into clinical care
  • Biologic rationale for and available data with anti-PD-1/PD-L1 antibodies combined with anti-CTLA-4 antibodies for previously untreated mUBC
  • Ongoing Phase III trials evaluating single or dual checkpoint inhibitor therapy, with or without chemotherapy, for treatment-naïve mUBC (eg, CheckMate 901, NILE)
  • Updated efficacy and safety findings from the Phase II EV-103 study evaluating first-line pembrolizumab in combination with enfortumab vedotin for mUBC; FDA breakthrough therapy designation and ongoing Phase III evaluation
  • Preliminary data with erdafitinib in combination with the investigational anti-PD-1 antibody cetrelimab in patients with previously untreated mUBC with FGFR3 or FGFR2 genetic alterations who are ineligible for cisplatin

MODULE 3: Later-Line Therapeutic Options for Patients with mUBC; Novel Investigational Strategies

  • Key findings with enfortumab vedotin in patients with progressive mUBC; FDA-approved indication and optimal incorporation into the treatment paradigm
  • Published efficacy and safety data with and current role of erdafitinib for patients with mUBC and susceptible FGFR3 or FGFR2 genetic alterations
  • Mechanism of action of sacituzumab govitecan; principal findings leading to FDA accelerated approval for progressive mUBC and optimal integration into clinical practice
  • Frequency, severity and management of adverse events reported with enfortumab vedotin, sacituzumab govitecan or erdafitinib for mUBC
  • Mechanism of action of the antibody-drug conjugate disitamab vedotin; available efficacy and safety findings and ongoing evaluation for HER2-overexpressing mUBC
  • Other promising agents and strategies under investigation for mUBC

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider available data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into current care.
  • Evaluate the recent FDA approval of adjuvant anti-PD-1 antibody therapy for high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this strategy.
  • Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for metastatic urothelial bladder carcinoma (UBC).
  • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic UBC, and determine the current utility of these agents in clinical practice.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with these approaches would be appropriate.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
  • Develop an understanding of the biologic rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for NMIBC, MIBC and metastatic UBC.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr LoriotAdvisory Committee: AstraZeneca Pharmaceuticals LP, Astellas, Basilea Pharmaceutica Ltd, Bristol-Myers Squibb Company, Gilead Sciences Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck KgaA, Merck Sharp & Dohme LLC, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Celsius Therapeutics, Janssen Biotech Inc, Merck Sharp & Dohme LLC, Roche Laboratories Inc, Sanofi Genzyme. Dr PlimackAdvisory Committee: Astellas, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Genentech, a member of the Roche Group, Janssen Biotech Inc, MEI Pharma Inc, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Contracted Research: Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Infinity Pharmaceuticals Inc. Dr RosenbergAdvisory Committee: Astellas, Seagen Inc; Consulting Agreements: Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Lilly, Merck, Mirati Therapeutics, Pfizer Inc, QED Therapeutics, Seagen Inc, Tyra Biosciences; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Seagen Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc; Honorarium: EMD Serono Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of bladder cancer.

There is no fee to participate in this program or live webcast of this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.